|
| |
Thrombotargets Corporation announces the incorporation of Steven Hite as a
Chief Operating Officer based in North Carolina, USA.
Durham, NC, June 1, 2007 – Thrombotargets Corp., a privately held
group of Biotech Company focused in the discovery and development of innovative
drugs, is pleased to announce the appointment of Steve A. Hite to Chief
Executive Officer. Reporting to the Executive Vice President, Dr. Caveda, Mr.
Hite will be responsible for Business Development Strategy, corporate
development, the development and enforcement of corporate policies and
procedures, and government affairs.
Mr Steven Hite has an extensive experience throughout the Far East in sales,
marketing and licensed business development over a wide variety of medical and
pharmaceutical products and services as well as extensive overseas business
assignments.
Mr Hite has successfully managed all aspects of two multinational corporate
start-ups in Tokyo, Japan and Princeton, New Jersey. As CEO and COO
respectively, effectively managed all functions of corporate operation for these
entities, leading the completion of an important worldwide product marketing
agreement.
“We are very pleased to have someone of Steve’s talent join Thrombotargets” says
Dr. Pedreño, president and Chief Executive Officer. “His extensive experience
and skills on the Pacific Rim and US Bio-Pharmaceutical markets will help
Thrombotargets to accomplish its business plans including the out license of
TT-103MH and the exploitation of BIOPLATFORMSCREEN HTS technologies.”
Upon joining Thrombotargets after his successful career at Taiho Pharma USA,
Inc., Mr. Hite stated: “I am very impressed with the products and technologies
of Thrombotargets, and I am excited to join this company and Work with Javier,
Luis and Thrombotargets’ strong management team. Thrombotargets has breakthrough
Technologies, first-in-class products and a flexible infrastructure upon which
to expand. I look forward to contributing to the continued growth of
Thrombotargets.”
Mr Steven Hite holds the BS graduation in, Business Management and Marketing and
after that he was serving for several relevant positions of business managing in
several companies worldwide.
About Thrombotargets Group
Thrombotargets has developed and adapted to High Throughput Screening, a new
family of biological assays, Hemosta-BIOPLATFORMSCREEN™, capable to quantify
simultaneously clot formation and clot lysis , Oxidant- BIOPLATFORMSCREEN™ to
quantify total antioxidant capacity and Athero- BIOPLATFORMSCREEN™, to quantify
low-density lipoprotein modification. With these proven proprietary new HTS
Platforms (BIOPLATFORMSCREEN™), Thrombotargets group is creating a continuously
novel and promising pipeline of drug candidates. TT-103MH, Thrombotargets’ most
advanced drug candidate, has recently been granted with an Orphan Drug
Designation, and will start Phase I clinical trials in early 2008.
Contact:
Luis Caveda Ph.D.
Thrombotargets Corp.
COO
luiscaveda@thrombotargets.com
| |
|
